Literature DB >> 1350744

Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.

J W Mandema1, M T Kuck, M Danhof.   

Abstract

1. The relevance of EEG effect parameters as a measure of the central nervous system effects of benzodiazepines was evaluated. The concentration-EEG effect relationships of the benzodiazepine agonist midazolam, partial agonist bretazenil, antagonist flumazenil and inverse agonist Ro 19-4603 were quantified and compared with the intrinsic efficacy and affinity of these compounds at the gamma-aminobutyric acid (GABA)-benzodiazepine receptor complex. 2. The pharmacokinetics and pharmacodynamics of the compounds were determined after a single intravenous bolus administration of 5 mg kg-1 midazolam, 2.5 mg kg-1 bretazenil, 10 mg kg-1 flumazenil or 2.5 mg kg-1 Ro 19-4603 to male Wistar derived rats. In a separate experiment the distribution between blood, cerebrospinal fluid and brain concentrations of these compounds was determined. A sensitive assay was developed to measure bretazenil and Ro 19-4603 concentrations in small samples of biological fluids. 3. The benzodiazepine-induced changes in amplitudes in the 11.5-30 Hz frequency band, as determined by aperiodic analysis, was used as EEG effect measure. Concentration-EEG effect relationships were derived by a pharmacokinetic-pharmacodynamic modelling procedure and in the case of midazolam, bretazenil and Ro 19-4603 successfully quantified by the sigmoidal Emax model. Large differences in maximal effect of midazolam (Emax = 73 +/- 2 microVs-1), bretazenil (Emax = 19 +/- 1 microVs-1) and Ro 19-4603 (Emax = -6.5 +/- 0.4 microVs-1) were observed, reflecting their differences in intrinsic efficacy. A close correlation was found between the EC50 values based on free drug concentration and receptor affinity as determined by displacement of [3H]-flumazenil in a washed brain homogenate at 37 degrees C. In the concentration range of receptor saturation flumazenil did not produce any changes in the EEG effect measure.4. The study demonstrated that the change in amplitudes in the 11.5-30 Hz frequency band of the EEG is a relevant measure of the pharmacological effect intensity of benzodiazepines, because it seems to reflect their affinity and intrinsic efficacy at the central GABA-benzodiazepine receptor complex.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350744      PMCID: PMC1908634          DOI: 10.1111/j.1476-5381.1992.tb14229.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Anxiogenic effects of a benzodiazepine receptor partial inverse agonist, RO 19-4603, in a light/dark choice situation.

Authors:  C Belzung; R Misslin; E Vogel
Journal:  Pharmacol Biochem Behav       Date:  1990-07       Impact factor: 3.533

2.  Partial agonists of the benzodiazepine receptor: from animal data to results in patients.

Authors:  W Haefely
Journal:  Adv Biochem Psychopharmacol       Date:  1988

Review 3.  Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview.

Authors:  J Dingemanse; M Danhof; D D Breimer
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

4.  Concentration-independent plasma protein binding of benzodiazepines.

Authors:  L J Moschitto; D J Greenblatt
Journal:  J Pharm Pharmacol       Date:  1983-03       Impact factor: 3.765

5.  Electrophysiological studies on the specific benzodiazepine antagonist Ro 15-1788.

Authors:  P Polc; J P Laurent; R Scherschlicht; W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-07       Impact factor: 3.000

6.  Inhibition of adenosine accumulation by a CNS benzodiazepine antagonist (Ro 15-1788) and a peripheral benzodiazepine receptor ligand (Ro 05-4864).

Authors:  P F Morgan; H G Lloyd; T W Stone
Journal:  Neurosci Lett       Date:  1983-10-31       Impact factor: 3.046

7.  Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure.

Authors:  J Dingemanse; F A Sollie; D D Breimer; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1988-04

8.  Demonstration of the partial agonist profiles of Ro 16-6028 and Ro 17-1812 in mice in vivo.

Authors:  M C Potier; L Prado de Carvalho; P Venault; G Chapouthier; J Rossier
Journal:  Eur J Pharmacol       Date:  1988-10-26       Impact factor: 4.432

Review 9.  Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity and therapeutic use.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

10.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

View more
  15 in total

1.  Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats.

Authors:  A Cleton; D Mazee; R A Voskuyl; M Danhof
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam.

Authors:  A Cleton; J Odman; P H Van der Graaf; W Ghijsen; R Voskuyl; M Danhof
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

3.  Enhancement of GABA-related signalling is associated with increase of functional connectivity in human cortex.

Authors:  Andrew A Fingelkurts; Alexander A Fingelkurts; Reetta Kivisaari; Eero Pekkonen; Risto J Ilmoniemi; Seppo Kähkönen
Journal:  Hum Brain Mapp       Date:  2004-05       Impact factor: 5.038

Review 4.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 5.  Pharmacokinetic-pharmacodynamic modelling in anaesthesia.

Authors:  Pedro L Gambús; Iñaki F Trocóniz
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 6.  Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Authors:  D D Breimer; M Danhof
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

7.  A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity.

Authors:  A L Van Steveninck; J W Mandema; B Tuk; J G Van Dijk; H C Schoemaker; M Danhof; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

Review 8.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

9.  Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol.

Authors:  Bert Tuk; Toon van Gool; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

10.  Behavioral effects of flumazenil in the social conflict test in mice.

Authors:  L Uhlírová; M Sustková-Fiserová; M Krsiak
Journal:  Psychopharmacology (Berl)       Date:  2003-09-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.